©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 10, 2016; 7(1): 106-113
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.106
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.106
Role of copper transporters in platinum resistance
Deepak Kilari, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States
Elizabeth Guancial, Eric S Kim, Departments of Medicine, University of Rochester Medical Center, Rochester, NY 14642, United States
Author contributions: All the authors contributed equally in writing the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Correspondence to: Eric S Kim, MD, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, United States. eric_kim@urmc.rochester.edu
Telephone: +1-585-2734150 Fax: +1-585-2731042
Received: May 29, 2015
Peer-review started: May 31, 2015
First decision: August 4, 2015
Revised: October 20, 2015
Accepted: November 23, 2015
Article in press: November 25, 2015
Published online: February 10, 2016
Processing time: 246 Days and 13.6 Hours
Peer-review started: May 31, 2015
First decision: August 4, 2015
Revised: October 20, 2015
Accepted: November 23, 2015
Article in press: November 25, 2015
Published online: February 10, 2016
Processing time: 246 Days and 13.6 Hours
Core Tip
Core tip: Platinum (Pt)-based chemotherapy is the backbone of treatment for various solid malignancies in both curative and palliative settings. However, the efficacy of Pt is limited by toxicity and inevitable resistance. Hence, it is important to understand the mechanisms of Pt resistance to not only identify treatment non-responders, but more importantly to help develop strategies to overcome resistance and improve efficacy. We herein discuss our current understanding of the mechanisms of Pt resistance, with a particular emphasis on the role of copper transporter receptor 1 in Pt resistance.